期刊文献+

噻托溴铵联合沙美特罗/丙酸氟替卡松治疗COPD稳定期患者的疗效观察 被引量:22

下载PDF
导出
摘要 目的观察联合吸入噻托溴铵和沙美特罗/丙酸氟替卡松对慢性阻塞性肺病(COPD)稳定期患者的疗效。方法采用随机、双盲的方法将85例COPD患者分为观察组和对照组,观察组给予噻托溴铵和沙美特罗/丙酸氟替卡松治疗,对照组给予沙美特罗/丙酸氟替卡松治疗。分别对两组患者治疗前后的临床症状积分(SGRQ)、肺功能的检测和6min步行距离(6MWT)的情况进行比较。结果SGRQ积分,两组治疗后均较治疗前有明显下降,而观察组下降比对照组更显著(<0.05);肺功能检测用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼吸气量占预计值的百分比(FEV1%)指标治疗后两组具有不同程度的改善,观察组肺功能指标优于对照组(<0.05);6MWT在治疗后两组均有一定的增加,但观察组较对照组增加的更加明显(<0.05)。结论联合吸入噻托溴铵和沙美特罗/丙酸氟替卡松治疗COPD稳定期患者不仅能够改善肺功能,而且能提高患者运动耐力和改善生活质量,具有较好的治疗效果。
作者 狄松波
出处 《现代实用医学》 2010年第2期210-211,共2页 Modern Practical Medicine
  • 相关文献

参考文献8

  • 1Pauwels RA, Buist AS, Calverley PM, et al. Global strategy forthe diagnosis,management,and prevention of chronic obstructivepulmonary disease. NHLBI/WHO Global Initiative for ChronicObstructive Lung Disease (GOld)) Workshop summary [J]. Am J Respir Crit Care Med,2001,163(5): 1256-1276.
  • 2慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量:5103
  • 3周玉民,冉丕鑫.慢性阻塞性肺疾病的流行病学[J].中国呼吸与危重监护杂志,2004,3(2):68-70. 被引量:122
  • 4CATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement: guidelines for the sixminute walk test[J]. Am J Respir Crit Care Med, 2002,166( 1): 111 - 117.
  • 5O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD [J]. Eur Respir J,2004,23(7):832-840.
  • 6Maltais F,Harciniuk D. Improvements in symptomlimited exercise performance over 8 h with oncedaily tiotropium in patients with COPD [J].Chest,2005,128(11): 1168-1178.
  • 7Jarvis B, Markham A. Inhaled salmeterol: a review of its efficiency in chronic obstructive pulmonary disease [J]. Drugs Aging,2001, 18(6):441-472.
  • 8Pauwels RA, Buist AS, Calverley PMA, et al. On behalfof the GOLD Scientific Committee.Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO GlobalInitiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary [JJ. Am J Respir Crit Care Med, 2001, 163(9): 1256-1276.

二级参考文献16

  • 1Stepnewski M, Kolarzyk E, Pietrzycka A, et al. Antioxidant enzymes and pulmonary function in steel mill welders. Int J Occup Med Environ Health, 2003 ; 16 : 41 - 47.
  • 2Golshan M, Faghihi M, Marardi MM. Indoor women jobs and pulmonary risks in rural areas of Isfahan, Iran, 2000. Respir Med, 2002 ; 96 : 382 -388.
  • 3Golshan M, Barahimi Hnasirian K. Prevalence of chronic bronchitis and chronic respiratory symptoms in adults over the age of 35 years in Isfahan,lran in 1998. Respirology.2001,6:231 - 235.
  • 4Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality and, disease heterogeneity. Chest, 2002 ; 121 : 121S - 126S.
  • 5Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance United States, 1971 - 2000. Respir Care,2002;47:1184 - 1199.
  • 6Lacasse Y, Brooks D, Goldstein RS. Trends in the Epidemiology of COPD in Canada, 1980 to 1995. Chest, 1999 ; 116:306 - 313.
  • 7Otero GI, Blanco AM, Montero MC. The epidemiology of COPD and asthma exacerbations in a general hospital. Arch Bronconeumol, 2002; 38:256 - 262.
  • 8Petty TL. Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone, 2003 ; 5 : 1 - 10.
  • 9Sin DD, Stafinski T, Ng YC, et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002 : 165 : 704 - 707.
  • 10Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects perspective of Confronting COPD International Survey. Eur Respir J, 2002 ; 20 : 799 - 805.

共引文献5211

同被引文献169

引证文献22

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部